The US HHS Secretary Mike Leavitt announced that the Department has awarded a $102.6 million, four-year contract to BioCryst Pharmaceuticals, Inc. for advanced development of their influenza antiviral drug, peramivir.
The Department of Health and Human Services (HHS), in a press release, said peramivir has been effective against several influenza strains in laboratory studies. HHS said the contract will cover production of the investigational drug, phase 2 and 3 clinical studies, and validation of manufacturing processes.
Research under the contract will include tests involving the deadly H5N1 avian flu virus and may include research on the possible preventive use of the drug, according to HHS. BioCryst officials said the drug has been shown to help animals survive H5N1 infection.
“Antivirals are an important element of our pandemic influenza preparedness efforts,” said HHS secretary Mike Leavitt in the press release. “Our antiviral strategy includes not only stockpiling existing antiviral drugs but also seeking out new antiviral medications to further broaden our capabilities to treat and prevent all forms of influenza.”
- « Folate :: Folate levels down in US women of childbearing age
- BSE :: US wants to end BSE-linked ban on older Canadian cattle »
Sub-editorFlu :: HHS awards $102 million for new flu drug
by Sub-editor ( Author at Spirit India )
Posted on January 7th, 2007 at 12:30 pm.
Find more from SpiritIndia on: Health